Literature DB >> 20572122

A flexible unified approach to the analysis of pre-clinical combination studies.

Chris Harbron1.   

Abstract

Combinations of drugs are increasingly being used in a variety of diseases. Pre-clinical experiments allow the responses of many drug compounds to be studied in combination with the goal of identifying compounds acting synergistically. This paper presents a unified approach to analysing data from combination studies, calculating a hierarchy of interaction indices to powerfully and flexibly describe the synergistic profile of the combination space studied, utilizing standard statistical software to generate estimates of confidence and provide statistical tests. The approach can work with a wide variety of experimental designs and response patterns and will deal with partial responses and inactive compounds. As well as identifying synergy or antagonism, the same approach can also be used to identify a benefit or detriment to monotherapy. The approach is illustrated with data from an in vitro study. Copyright (c) 2010 John Wiley & Sons, Ltd

Mesh:

Substances:

Year:  2010        PMID: 20572122     DOI: 10.1002/sim.3916

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  10 in total

1.  MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition.

Authors:  Christina M Knippler; Motoyasu Saji; Neel Rajan; Kyle Porter; Krista M D La Perle; Matthew D Ringel
Journal:  Endocr Relat Cancer       Date:  2019-08       Impact factor: 5.678

2.  Monotonic single-index models to assess drug interactions.

Authors:  Yubing Wan; Susmita Datta; J Jack Lee; Maiying Kong
Journal:  Stat Med       Date:  2016-11-02       Impact factor: 2.373

3.  Erlotinib antagonizes ABC transporters in acute myeloid leukemia.

Authors:  Elodie Lainey; Marie Sébert; Sylvain Thépot; Marie Scoazec; Cyrielle Bouteloup; Carole Leroy; Stéphane De Botton; Lorenzo Galluzzi; Pierre Fenaux; Guido Kroemer
Journal:  Cell Cycle       Date:  2012-10-24       Impact factor: 4.534

4.  Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer.

Authors:  Judith Michels; Ilio Vitale; Laura Senovilla; David P Enot; Pauline Garcia; Delphine Lissa; Ken A Olaussen; Catherine Brenner; Jean-Charles Soria; Maria Castedo; Guido Kroemer
Journal:  Cell Cycle       Date:  2013-02-21       Impact factor: 4.534

5.  Corticosteroid insensitive alveolar macrophages from asthma patients; synergistic interaction with a p38 mitogen-activated protein kinase (MAPK) inhibitor.

Authors:  Simon Lea; Chris Harbron; Naimat Khan; George Booth; Jane Armstrong; Dave Singh
Journal:  Br J Clin Pharmacol       Date:  2015-05       Impact factor: 4.335

6.  BIGL: Biochemically Intuitive Generalized Loewe null model for prediction of the expected combined effect compatible with partial agonism and antagonism.

Authors:  Koen Van der Borght; Annelies Tourny; Rytis Bagdziunas; Olivier Thas; Maxim Nazarov; Heather Turner; Bie Verbist; Hugo Ceulemans
Journal:  Sci Rep       Date:  2017-12-20       Impact factor: 4.379

7.  Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma.

Authors:  Ileabett M Echevarría-Vargas; Patricia I Reyes-Uribe; Adam N Guterres; Xiangfan Yin; Andrew V Kossenkov; Qin Liu; Gao Zhang; Clemens Krepler; Chaoran Cheng; Zhi Wei; Rajasekharan Somasundaram; Giorgos Karakousis; Wei Xu; Jennifer Jd Morrissette; Yiling Lu; Gordon B Mills; Ryan J Sullivan; Miao Benchun; Dennie T Frederick; Genevieve Boland; Keith T Flaherty; Ashani T Weeraratna; Meenhard Herlyn; Ravi Amaravadi; Lynn M Schuchter; Christin E Burd; Andrew E Aplin; Xiaowei Xu; Jessie Villanueva
Journal:  EMBO Mol Med       Date:  2018-05       Impact factor: 12.137

8.  Pentoxifylline, dexamethasone and azithromycin demonstrate distinct age-dependent and synergistic inhibition of TLR- and inflammasome-mediated cytokine production in human newborn and adult blood in vitro.

Authors:  Esther M Speer; David J Dowling; Jianjin Xu; Lukasz S Ozog; Jaime A Mathew; Avinash Chander; Donglei Yin; Ofer Levy
Journal:  PLoS One       Date:  2018-05-01       Impact factor: 3.240

9.  P38 MAPK and glucocorticoid receptor crosstalk in bronchial epithelial cells.

Authors:  Simon Lea; Jian Li; Jonathan Plumb; Kate Gaffey; Sarah Mason; Rosie Gaskell; Chris Harbron; Dave Singh
Journal:  J Mol Med (Berl)       Date:  2020-01-23       Impact factor: 4.599

10.  Bliss' and Loewe's additive and synergistic effects in Plasmodium falciparum growth inhibition by AMA1-RON2L, RH5, RIPR and CyRPA antibody combinations.

Authors:  Yvonne Azasi; Shannon K Gallagher; Ababacar Diouf; Rebecca A Dabbs; Jing Jin; Syed Yusuf Mian; David L Narum; Carole A Long; Deepak Gaur; Simon J Draper; Michael P Fay; Louis H Miller; Kazutoyo Miura
Journal:  Sci Rep       Date:  2020-07-16       Impact factor: 4.996

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.